🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Shalby Limited SHALBY NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.shalby.org

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; and interventional and diagnostic radiology. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.

READ MORE ›
₹168.81
-14.32% 1Y

Market & Price

Market Cap
₹1,811.31 Cr
Current Price
₹168.81
High / Low (52W)
₹266.83 / ₹126.80
Beta
0.61

Valuation

Stock P/E
216.42
Industry PE
37.60
Forward P/E
17.96
PEG Ratio
-
Book Value
₹92.31
Price to Book
1.83
P/S
1.62
EV/EBITDA
17.25
Dividend Yield
-

Profitability & Returns

ROCE
7.29%
ROE
-
ROA
-
Profit Margin
0.72%
Op Margin
4.65%
EPS (Latest Qtr)
₹0.12
EPS (TTM)
₹0.78

Balance Sheet & Liquidity

Debt/Equity
0.53
Quick Ratio
-
Current Ratio
-
Debt
₹534.69 Cr
Total Assets
₹1,703.65 Cr
Current Assets
₹657.96 Cr
Working Capital
₹202.64 Cr

Ownership

Promoter Holding
76.47%
Chg in Prom Hold
-
FII / Inst Holding
0.07%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹2,368.80 Cr
Total Revenue (TTM)
₹1,118.88 Cr
EBITDA
₹137.32 Cr
Free Cash Flow
-
Operating Cash Flow
-
Shares Outstanding
₹10.73 Cr
Gross Margin
21.39%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
15.64%
Profit 5Y
-51.38%
Revenue (YoY)
-1.30%
Earnings (YoY)
-

PROS

  • Compounding revenue at 15.6% over 5 years.

CONS

  • Trading at a high P/E of 216.4.
  • Earnings shrank at -51.4% CAGR over 5 years.
  • Trading 36.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SHALBY Shalby Limited NSEPHARMA 168.81 216.42 ₹1,811.31 Cr - 7.29% - 15.64% -51.38%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue -275.63 Cr258.71 Cr296.43 Cr285.43 Cr272.13 Cr
Cost of Revenue -153.22 Cr165.57 Cr178.86 Cr163.76 Cr160.25 Cr
Gross Profit -122.42 Cr93.14 Cr117.56 Cr121.67 Cr111.88 Cr
Operating Expenses -104.83 Cr77.43 Cr92.55 Cr97.43 Cr99.24 Cr
Operating Income -17.59 Cr15.71 Cr25.02 Cr24.24 Cr12.64 Cr
EBITDA -39.33 Cr22.72 Cr48.55 Cr46.09 Cr37.48 Cr
Interest Expense -10.66 Cr7.23 Cr9.37 Cr9.64 Cr10.64 Cr
Pretax Income -12.35 Cr-73.80 L22.65 Cr19.07 Cr9.23 Cr
Tax Provision -15.34 Cr11.45 Cr14.97 Cr11.80 Cr7.95 Cr
Net Income --1.81 Cr-11.02 Cr8.92 Cr8.38 Cr1.76 Cr
Diluted EPS 0.22-0.28-0.710.680.12

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025
Revenue 698.95 Cr799.63 Cr928.22 Cr1,080.77 Cr
Cost of Revenue 394.32 Cr435.11 Cr505.18 Cr634.97 Cr
Gross Profit 304.63 Cr364.52 Cr423.04 Cr445.80 Cr
Operating Expenses 222.01 Cr270.75 Cr294.70 Cr367.86 Cr
Operating Income 82.62 Cr93.77 Cr128.34 Cr77.94 Cr
EBITDA 127.90 Cr158.10 Cr194.83 Cr156.76 Cr
Interest Expense 5.88 Cr7.97 Cr14.40 Cr35.27 Cr
Pretax Income 79.15 Cr102.04 Cr128.19 Cr55.73 Cr
Tax Provision 25.18 Cr34.37 Cr44.69 Cr53.81 Cr
Net Income 54.12 Cr67.70 Cr84.08 Cr6.22 Cr
Diluted EPS 5.006.307.830.58

Compounded Sales Growth

5 Years:15.64%
1 Year:-1.30%

Compounded Profit Growth

5 Years:-51.38%
1 Year:-

Stock Price Performance

1 Year:-14.32%
6 Months:-19.98%
3 Months:+11.13%
1 Month:+5.07%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets 1,193.54 Cr1,281.36 Cr1,607.53 Cr1,703.65 Cr
Current Assets 448.87 Cr517.25 Cr552.25 Cr657.96 Cr
Cash & Equivalents 55.55 Cr12.24 Cr27.18 Cr34.78 Cr
Inventory 121.12 Cr185.40 Cr235.20 Cr319.21 Cr
Receivables 100.99 Cr106.36 Cr144.63 Cr175.21 Cr
Total Liabilities 317.35 Cr353.75 Cr599.75 Cr708.33 Cr
Current Liabilities 172.46 Cr194.38 Cr323.27 Cr455.32 Cr
Long Term Debt 87.39 Cr67.42 Cr175.97 Cr136.67 Cr
Total Debt 174.07 Cr180.50 Cr377.87 Cr475.93 Cr
Total Equity 876.32 Cr927.68 Cr1,000.37 Cr992.19 Cr
Shares Outstanding 10.80 Cr10.80 Cr10.80 Cr10.80 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow 18.92 Cr67.78 Cr19.60 Cr-4.34 Cr
Investing Cash Flow -60.30 Cr-61.08 Cr38.07 Cr-35.64 Cr
Financing Cash Flow 90.46 Cr-50.02 Cr-150.69 Cr47.58 Cr
Capital Expenditure -75.39 Cr-18.48 Cr-47.11 Cr-71.45 Cr
Free Cash Flow -56.48 Cr49.29 Cr-27.51 Cr-75.79 Cr
Net Change in Cash 49.07 Cr-43.33 Cr-93.02 Cr7.60 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025
Gross Margin % 43.6%45.6%45.6%41.2%
Operating Margin % 11.8%11.7%13.8%7.2%
Net Margin % 7.7%8.5%9.1%0.6%
ROE % 6.2%7.3%8.4%0.6%
ROCE % 8.1%8.6%10.0%6.2%

Shareholding Pattern

Insiders
76.47%
Institutions
0.07%
Public Float
0.27%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SHALBY

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks